Tecartus (brexucabtagene autoleucel)

pCPA File Number: 21582
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Sponsor/Manufacturer:
Gilead Sciences Canada Inc.
CADTH Project Number:
PG0219-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable